QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BNTX

QT63BioNTech SE
NASDAQ·Healthcare·Biotechnology·Germany
Latest market price
90.89
-1.33-1.44%
OverviewShort InterestFilings
BNTXQT63BioNTech SE·NASDAQ
OverviewShort InterestFilings
90.89-1.44%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59RPRX-1.38%$52.96
Snapshot
Index-P/E-EPS (ttm)
-5.89
Insider Own0.18%
Shs Outstand252.88M
Perf Week1.51%
Market Cap23.31BForward P/E-EPS next Y-5.48Insider Trans-0.02%Shs Float-Perf Month3.53%
Enterprise Value12.26BPEG0.17EPS next Q-2.80Inst Own-Short Float-Perf Quarter1.77%
Income-1431462364.00P/S7.27EPS this Y9.29%Inst Trans-Short Ratio-Perf Half Y-1.45%
Sales3.21BP/B1.09EPS next Y-2.62%ROA-5.93%Short Interest-Perf YTD-4.53%
Book/sh85.56P/C23.30EPS next 5Y-ROE-6.67%52W High124.00 -26.70%Perf Year-13.41%
Cash/sh66.98P/FCF29.84EPS past 3/5Y-ROIC-7.52%52W Low79.52 14.30%Perf 3Y-
Dividend Est.-EV/EBITDA-15.24Sales past 3/5Y-44.51% 41.41%Gross Margin77.60%Volatility1.70% 2.05%Perf 5Y-
Dividend TTM-EV/Sales3.82EPS Y/Y TTM-54.16%Oper. Margin-52.06%ATR (14)2.91Perf 10Y-
Dividend Ex-DateJun 02, 2022Quick Ratio8.74Sales Y/Y TTM9.54%Profit Margin-44.67%RSI (14)49.42Recom2.22
Dividend Gr. 3/5Y-Current Ratio8.80EPS Q/Q-25.27%SMA200.64%Beta0.97Target Price135.00
Payout0.00%Debt/Eq0.02Sales Q/Q-26.56%SMA50-4.16%Rel Volume0.94Prev Close92.22
Employees6,772LT Debt/Eq0.01EarningsAug 03SMA200-8.71%Avg Volume999.19KPrice90.89
IPO DateOct 10, 2019Option/ShortYes / YesEPS/Sales Surpr.9.52% -34.30%Net Debt/EBITDA13.73Volume937,157Change-1.44%
Analyst Ratings
DateActionAnalystRatingTarget
May-27-26UpgradeUBSNeutral → Buy$168 → $135
May-21-26InitiatedBernsteinMarket Perform$96
May-06-26ReiteratedCanaccord GenuityBuy$171 → $158
Apr-10-26ReiteratedMorgan StanleyOverweight$128 → $126
Mar-11-26ReiteratedBMO CapitalOutperform$126 → $128
Mar-10-26ReiteratedTruist Financial$155
Mar-10-26ReiteratedJefferiesBuy$150 → $138
Feb-02-26ReiteratedLeerink Partners$112 → $113
Jan-16-26UpgradeGoldman SachsNeutral → Buy$110 → $142
Dec-11-25ReiteratedBerenberg Bank$150 → $155
Latest News
Jun-17-26
Jun-17-2612:18PM
'BioNTech Investor Förtsch Says Founders' Spinout Raises Concerns' - Bloomberg NewsBenzinga
Jun-09-26
Jun-09-2605:41PM
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 StudyYahoo
Jun-08-26
Jun-08-2603:11PM
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth SignalsYahoo
03:11PM
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth SignalsYahoo
03:11PM
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth SignalsYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,2603,1102,976
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A873695586
Gross Profit2,3842,4142,391
Selling, General and Administrative Excl. Other847788648
Research and Development2,4832,2812,439
Other Operating Expense73349726
Operating Income-1,679-704-1,422
Interest Expense161514
Unusual Expense
———
Non-Operating Income (Expense)-328419-702
Net Income Before Taxes-1,365-1,139-733
Income Taxes9192-13
Consolidated Net Income-1,457-1,231-720
Net Income From Continuing Operations-1,457-1,231-720
Net Income-1,457-1,231-720
EPS (Recurring)-5.89-5.09-3.00
EPS (Basic, Before Extraordinaries)-5.89-5.09-3.00
EPS (Diluted)-5.89-5.09-3.00
EBITDA-812-708-397
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio7.057.41—
Gross Margin73.1377.6280.34
Operating Margin-51.50-22.64-47.78
Net Margin-44.69-39.58-24.19
Shares Outstanding253242240
Market Capitalization22,99523,038—
Operating Lease Expense
———
Insider Trading Volume
$103.60$95.09$86.58$78.06$69.55● Close Price0.00M1.38M2.76M4.15M5.53MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Poetting SierkChief Operating OfficerApr 22 '26Sale110.5650,0005,527,960399,387Apr 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR